regardless of promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable difficulty from managed care entities. Such companies are often erecting barriers to reimbursement, such as significant cost restrictions a